No Data
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics Price Target Cut to $50.00/Share From $90.00 by Truist Securities
Truist Financial Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $50
Truist Financial Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Announces Target Price $50
Evercore ISI Sticks to Their Buy Rating for Intellia Therapeutics (NTLA)
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
102269728 OP : experts, can help explain to me noob please?
alson102446937 102269728 OP : pioneer in Cas9, while Q report beat estimation.